Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

NVS vs MRK: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

NVS Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 5–4 Matrix Metrics)

NVS Overall Winner 6-Pillar Tally: NVS 4 – 2 MRK Matrix Metrics: NVS 5 – 4 MRK

As of Nov 16, 2026, Novartis AG (NVS) is the stronger overall head-to-head candidate over Merck & Co., Inc. (MRK) in the Tradestie Institutional Equity Comparison Engine, winning 5–4 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). NVS carries a Unified Composite Score of 41.5/100 (SELL) at $161.59 (16.2x Forward P/E, 34.0% operating margin), whereas MRK carries 57.1/100 (HOLD) at $146.35 (16.4x Forward P/E, 35.2% operating margin).

  • Composite vs. Pillar Nuance: While MRK currently prints a higher short-term Unified Composite Score (57.1/100 HOLD vs. NVS 41.5/100 SELL), NVS captures the overall institutional head-to-head verdict (5–4 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (34.0% vs. 35.2% operating margin) and revenue trajectory (+4.7% vs. +4.7% YoY).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About NVS vs MRK
NVS NYSE Head-to-Head Winner
Novartis AG
Pharmaceutical Preparations
$161.59
+0.68% 1D
Market Cap $302.9B
TTM Revenue $40.5B
Forward P/E 16.2x
Beta / 30D Vol 0.31β · 27% Vol
Unified Composite Score
41.5 / 100 SELL
Tech 29.0 Fund 38.0 Flow 50.0 Mom 21.1
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (0.7% over 20 days), RSI 61
RSI-14: 60.8 · SMA20: $159.19 · SMA50: $149.17
MRK NYSE
Merck & Co., Inc.
Pharmaceutical Preparations
$146.35
-0.95% 1D
Market Cap $362.3B
TTM Revenue $67.4B
Forward P/E 16.4x
Beta / 30D Vol 0.19β · 31% Vol
Unified Composite Score
57.1 / 100 HOLD
Tech 48.0 Fund 65.0 Flow 67.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 51
RSI-14: 51.2 · SMA20: $146.63 · SMA50: $146.07

6-Pillar Scorecard Institutional Category Breakdown (NVS 4 – 2 MRK)

Columns: Metric · NVS · MRK
1. Valuation Multiples NVS
Forward P/E 16.2x 16.4x
Trailing P/E 30.6x 148.4x
PEG Ratio 3.81x 3.56x
EV / Revenue 7.5x 6.0x
2. Growth & Scale MRK
Revenue Growth (YoY) +4.7% +4.7%
Earnings Growth (YoY) -68.8% -12.0%
TTM Revenue (USD) $40.5B $67.4B
Market Cap $302.9B $362.3B
3. Profitability & Quality NVS
Gross Margin 75.2% 75.2%
Operating Margin 34.0% 35.2%
Net Profit Margin 17.5% 3.6%
Return on Equity (ROE) 24.3% 5.1%
4. Balance Sheet & Cash Flow NVS
Cash Generation (TTM) $17.0B EBITDA $14.7B
Cash Flow Margin 42.0% EBITDA Mgn 21.9%
Net Cash / Leverage $19.71 Book/Sh · 24.3% ROE $44.2B Net Debt (1.20x D/E)
Dividend Yield 2.96% 2.28%
5. Options & Positioning MRK
Options Structure Phase UNCLASSIFIED CONSOLIDATION
Current IV / %ile 16.9% (6th %ile) 110.2% (100th %ile)
Put/Call OI Skew Thin ADR Chain 0.52x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markup DISTRIBUTION · Neutral
6. R&D & Supply-Chain Moat NVS
OpEx & R&D Intensity 41.2% of Rev ($16.7B) 40.0% of Rev ($27.0B)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat High-Margin Pricing Power Moat High-Margin Pricing Power Moat
Supply-Chain Role Drug Manufacturers - General Operator Drug Manufacturers - General Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: NVS (5) vs MRK (4)
Institutional Metric NVS MRK Criterion Row Edge
Market Capitalization
Scale
$302.9B $362.3B Larger Scale MRK
Trailing P/E Ratio
Valuation
30.6x 148.4x Lower Multiple NVS
Forward P/E Ratio
Valuation
16.2x 16.4x Lower Multiple NVS
Revenue Growth (YoY)
Growth
+4.7% +4.7% Higher Growth Tie
Operating Margin (TTM)
Profitability
34.0% 35.2% Higher Margin MRK
Net Profit Margin
Profitability
17.5% 3.6% Higher Margin NVS
Return on Equity (ROE)
Capital Efficiency
24.3% 5.1% Higher ROE NVS
52-Week Range Position
Momentum
81% ($123–$170) 84% ($91–$157) Stronger Trend MRK
Beta / 30D Volatility
Risk Regime
0.31β · 27% Vol 0.19β · 31% Vol Lower Realized Risk NVS
Unified Institutional Score
Composite Signal
41.5 / 100 (SELL) 57.1 / 100 (HOLD) Higher Composite MRK
Trailing 12M Revenue (USD)
Operating Scale
$40.5B $67.4B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
75.2% 75.2% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
3.81x PEG · 7.5x EV/Rev 3.56x PEG · 6.0x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$17.0B EBITDA ($19.71 Book/Sh · 24.3% ROE) $14.7B ($44.2B Net Debt (1.20x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon NVS +7.01 pp
NVS: +7.28% · MRK: +0.27%
3M Horizon MRK +3.71 pp
NVS: +4.56% · MRK: +8.27%
6M Horizon MRK +21.68 pp
NVS: +8.34% · MRK: +30.02%
1Y Horizon MRK +34.98 pp
NVS: +22.5% · MRK: +57.48%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on NVS vs MRK. Trailing 12-month operating profitability (NVS 34.0% vs MRK 35.2%) and valuation multiples (NVS 16.2x vs MRK 16.4x Forward P/E) are benchmarked directly in Pillar 4 below.

NVS ADR TTM Benchmark FX-Normalized USD
TTM Revenue$40.5B
Gross Margin75.2%
Op. Margin34.0%
ROE / Fwd P/E24.3% · 16.2x
MRK ADR TTM Benchmark FX-Normalized USD
TTM Revenue$67.4B
Gross Margin75.2%
Op. Margin35.2%
ROE / Fwd P/E5.1% · 16.4x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
NVS UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 16.9%
IV Percentile 6th %ile
Put/Call OI Skew Thin ADR Chain
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact NVS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
MRK CONSOLIDATION
57d in phase · OBV DISTRIBUTION
Current IV 110.2%
IV Percentile 100th %ile
Put/Call OI Skew 0.52x (Call-Skewed)
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact MRK Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
NVS Moat Profile High-Margin Pricing Power Moat
Drug Manufacturers - General Operator
Competes within the Drug Manufacturers - General value chain with $302.9B market capitalization and 34.0% operating margin.
OpEx & R&D Reinvestment 41.2% of Rev ($16.7B)
90D Engineering Disclosures 0 Published
MRK Moat Profile High-Margin Pricing Power Moat
Drug Manufacturers - General Operator
Competes within the Drug Manufacturers - General value chain with $362.3B market capitalization and 35.2% operating margin.
OpEx & R&D Reinvestment 40.0% of Rev ($27.0B)
90D Engineering Disclosures 0 Published

Investor FAQ NVS vs MRK Key Questions & Quantitative Answers

As of Nov 16, 2026, Novartis AG (NVS) is the stronger overall head-to-head candidate over Merck & Co., Inc. (MRK) in the Tradestie Institutional Equity Comparison Engine, winning 5–4 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). NVS carries a Unified Composite Score of 41.5/100 (SELL) at $161.59 (16.2x Forward P/E, 34.0% operating margin), whereas MRK carries 57.1/100 (HOLD) at $146.35 (16.4x Forward P/E, 35.2% operating margin). Composite vs. Pillar Nuance: While MRK currently prints a higher short-term Unified Composite Score (57.1/100 HOLD vs. NVS 41.5/100 SELL), NVS captures the overall institutional head-to-head verdict (5–4 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (34.0% vs. 35.2% operating margin) and revenue trajectory (+4.7% vs. +4.7% YoY).

MRK leads the Growth & Scale pillar: NVS posts +4.7% YoY revenue growth and -68.8% YoY earnings growth on $40.5B TTM revenue (75.2% gross margin, 34.0% operating margin), compared with MRK at +4.7% YoY revenue growth and -12.0% YoY earnings growth on $67.4B TTM revenue (75.2% gross margin, 35.2% operating margin). On trailing 12-month operating scale, NVS generates $40.5B in USD-normalized revenue versus $67.4B for MRK. In operating R&D and SG&A reinvestment, NVS deploys 41.2% of Rev ($16.7B) (0 90-day corporate R&D disclosures) versus 40.0% of Rev ($27.0B) (0 disclosures) for MRK.

NVS screens cheaper on headline valuation multiples. NVS trades at 16.2x Forward P/E, 30.6x Trailing P/E, 3.81x PEG, and 7.5x EV/Revenue (42.0% EBITDA margin), whereas MRK trades at 16.4x Forward P/E, 148.4x Trailing P/E, 3.56x PEG, and 6.0x EV/Revenue (21.9% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against NVS (24.3% ROE) versus MRK (5.1% ROE) capital efficiency.

In options market volatility and institutional positioning, NVS carries 16.9% implied volatility (6th %ile, Compressed (<25th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.31β · 27% Vol realized risk). By comparison, MRK carries 110.2% implied volatility (100th %ile, Extreme (>80th %ile)), a 0.52x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.19β · 31% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.